Clinical Trial Update: Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing gemcitabine and docetaxel in relapsed or refractory ovarian epithelial or peritoneal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Robert Morris | Conditions: Ovarian Cancer, Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-02-09